期刊
JOURNAL OF CLINICAL MICROBIOLOGY
卷 52, 期 3, 页码 994-997出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.03044-13
关键词
-
类别
资金
- Pfizer
- Merck
- Basilea
- Astellas
- Viamet
- bioMerieux
- Medicis
We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据